The most effective drug for Alzheimer’s has been blocked for use on the NHS. Regulators have declared the new treatment for the disease safe for use but the rationing body has immediately ruled that it is too expensive for NHS patients.

A new Alzheimer’s drug has been rejected for widespread use in the health service in England after the health spending watchdog said it “does not currently demonstrate value for the NHS”.The news comes as the UK’s medicines regulator said donanemab could be licensed for use in the UK.

A new Alzheimer’s drug has been rejected for widespread use in the NHS in England after the health spending watchdog ruled it “does not currently demonstrate value for the NHS ”. The new drug, called donanemab, has been rejected for use in England’s health services by the National Institute for Health and Care Excellence ( NICE ).